American Association for Cancer Research
Browse
00085472can161134-sup-165252_1_supp_3628548_cc09xc.docx (107.66 kB)

Supplementary Table S3 from PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells

Download (107.66 kB)
journal contribution
posted on 2023-03-31, 00:30 authored by Amanpreet Kaur, Oxana V. Denisova, Xi Qiao, Mikael Jumppanen, Emilia Peuhu, Shafiq U. Ahmed, Olayinka Raheem, Hannu Haapasalo, John Eriksson, Anthony J. Chalmers, Pirjo Laakkonen, Jukka Westermarck

Structure-activity relationship (SAR) analysis of STS derivatives to identify active synthetic lethality in PME-1 depleted cells.

Funding

Academy of Finland

History

ARTICLE ABSTRACT

Glioblastoma multiforme lacks effective therapy options. Although deregulated kinase pathways are drivers of malignant progression in glioblastoma multiforme, glioma cells exhibit intrinsic resistance toward many kinase inhibitors, and the molecular basis of this resistance remains poorly understood. Here, we show that overexpression of the protein phosphatase 2A (PP2A) inhibitor protein PME-1 drives resistance of glioma cells to various multikinase inhibitors. The PME-1–elicited resistance was dependent on specific PP2A complexes and was mediated by a decrease in cytoplasmic HDAC4 activity. Importantly, both PME-1 and HDAC4 associated with human glioma progression, supporting clinical relevance of the identified mechanism. Synthetic lethality induced by both PME-1 and HDAC4 inhibition was dependent on the coexpression of proapoptotic protein BAD. Thus, PME-1–mediated PP2A inhibition is a novel mechanistic explanation for multikinase inhibitor resistance in glioma cells. Clinically, these results may inform patient stratification strategies for future clinical trials with selected kinase inhibitors in glioblastoma multiforme. Cancer Res; 76(23); 7001–11. ©2016 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC